PYC Wins EMA Orphan Status for RP11 Gene Therapy Candidate VP-001

PYC Therapeutics Limited ( (AU:PYC) ) has provided an announcement.

PYC Therapeutics has secured Orphan Drug Designation from the European Medicines Agency for VP-001, its investigational therapy for Retinitis Pigmentosa type 11, a rare blinding eye disease with no approved treatments. The status provides 10 years of market exclusivity in Europe upon approval, access to EMA scientific advice on clinical development, and reduced regulatory fees, reinforcing VP-001’s commercial and regulatory attractiveness.

The EMA designation adds to VP-001’s existing U.S. FDA incentives, including Orphan Drug, Fast Track and Rare Pediatric Disease designations, strengthening the candidate’s global regulatory profile. PYC is using recent FDA guidance as it awaits additional Phase 2 data to optimize the design of a proposed registrational trial, a key step toward a potential future approval and a meaningful new option for RP11 patients.

The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.84 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

More about PYC Therapeutics Limited

PYC Therapeutics Limited is an ASX-listed, clinical-stage biotechnology company focused on precision RNA therapies for genetic diseases. The company leverages a proprietary drug delivery platform to enhance the potency of RNA-based medicines and currently runs three clinical-stage programs targeting monogenic indications with high probability of clinical success.

Average Trading Volume: 1,466,893

Technical Sentiment Signal: Buy

Current Market Cap: A$1.27B

See more insights into PYC stock on TipRanks’ Stock Analysis page.